South Korean biopharmaceutical firm GC Pharma has partnered with US-based Speragen to develop an enzyme replacement therapy for succinic semialdehyde dehydrogenase deficiency, reported The Korea Herald.

The two companies aim to start preclinical studies this year and Phase I and II tetsing during the second half of 2023.

Under the partnership, GC Pharma will be responsible for the overall drug discovery and development process, including biomarker research and clinical studies.

Meanwhile, Speragen will meet with the FDa for patient-focused drug development meetings, designed to take the patient into account throughout the entire drug development.

Speragen will be also responsible for recruiting patients for upcoming clinical trials.